PharmaBoardroom

The Value Proposition of Generics & Biosimilars in the USA

AAM President Dan Leonard highlights the findings of the association’s most recent report and re-states the value proposition of generic and…

Kirsti Nyhus – Market Access & External Affairs…

AbbVie Norway’s Kirsti Nyhus discusses access challenges in the Norwegian market for innovative drugs, the importance of bringing clinical trials…

Jürg Utzinger – Director, Swiss Tropical & Public…

Prof Dr Jürg Utzinger of the Swiss Tropical and Public Health Institute (Swiss TPH) outlines the organisation’s important role within the global…

Why Europe Needs a Sustainable Pharma Manufacturing System

On 25 November, the European Commission adopted a new strategy meant to, among others, allow Europe to cover its pharmaceutical needs, including in…

Chinese Pharma Share Price Hit; Pfizer-LianBio Linkup; Novo’s…

The latest from Chinese pharma, including a drop in share prices for Chinese vaccine firms in the wake of successful COVID-19 trial results from…

Ana Hidalgo-Simon – Head of Advanced Therapies, European…

The EMA’s Head of Advanced Therapies Dr Ana Hidalgo-Simon outlines Europe’s evolving regulatory framework for regenerative medicines, how it…

Asia-Pacific: World’s Largest Trade Deal’s Pharma Impact Too…

On 15 November 2020, the world’s largest trade deal in terms of GDP – the Regional Comprehensive Economic Partnership (RCEP) –was signed…

Cross Country Collaborations in Europe: The Future of Pricing…

Merck VP for Global Market Access & Pricing Strategic Planning Marco Rauland examines the trend of collaboration between European countries…

Rare Disease Strategies in the Booming US Market

Rare disease – defined in the US as a disease with a maximum patient population of 200,000 – is perhaps the most salient issue at the nexus of…

Novartis Oncology US: Leaning into Change

With a series of reorganization initiatives, new leaders at the helm and exciting acquisitions, Novartis Oncology has undergone a significant business…

Annalise Eggimann – CEO, Innosuisse

Innosuisse CEO Annalise Eggimann presents the organisation’s renewed mandate as the main Swiss innovation promotion agency, how Innosuisse serves…

Novartis Oncology President: “If We Offer Pay-For-Performance,…

During the FT Global Pharmaceutical and Biotechnology Conference earlier this month, three industry leaders spoke about innovative reimbursement…

Tagged with R